Skip to main content
SpringerLink
Log in

Utilization of Site-Specific Recombination for Generating Therapeutic Protein Producing Cell Lines

  • Research
  • Published:
Molecular Biotechnology Aims and scope Submit manuscript

Abstract

The AttSite® Recombinase Technology from Intrexon, Blacksburg, VA, utilizes specific DNA sequences and proprietary recombinase enzymes to catalyze the insertion of a gene of interest at a specific location in the host cell genome. Using this technology, we have developed Chinese Hamster Ovary (CHO) cell lines that have incorporated attB recombination sites at highly transcriptionally active loci or ‘hot spots’ within the cell genome. Subsequently, these attB site containing host cell lines could then be used for the expression of future Centocor products. Candidate production cell lines would be generated by a simple recombination event. Since the therapeutic gene of interest would preferentially integrate into the pre-selected high-expressing attB site, candidate cell lines would consistently express high levels of the gene of interest. We have been able to demonstrate that the AttSite® Recombinase Technology could be a valid approach for the development of high-expressing production cell lines.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Labrador, M., & Corces, V. G. (2002). Setting the boundaries of chromatin domains and nuclear organization. Cell, 111(2), 151–154.

    Article  CAS  Google Scholar 

  2. Branda, C. S., & Dymecki, S. M. (2004). Talking about a revolution: The impact of site-specific recombinases on genetic analyses in mice. Developmental Cell, 6(1), 7–28.

    Article  CAS  Google Scholar 

  3. Groth, A. C., & Carlos, M. P. (2004). Phage integrases: Biology and applications. Journal of Molecular Biology, 335, 667–678.

    Article  CAS  Google Scholar 

  4. Smith, M. C., & Thorpe, H. M. (2002). Diversity in the serine recombinases. Molecular Microbiology, 44(2), 299–307.

    Article  CAS  Google Scholar 

  5. Russell, J. P., Chang, D. W., Tretiakova, A., & Padidam, M. (2006). Phage Bxb1 integrase mediates highly efficient site-specific recombination in mammalian cells. BioTechniques, 40, 460–464.

    Article  CAS  Google Scholar 

  6. Patent: Site-specific serine recombinases and methods of their use. U.S. Provisional Patent Application 20080020465. Filed 08/20/2007. Inventors: Padidam, M.

Download references

Author information

Authors and Affiliations

  1. Pharmaceutical Development, Gene Expression, Centocor R&D Inc., Radnor, PA, USA

    Margie Campbell, Susanne Corisdeo, Clair McGee & Denny Kraichely

Authors
  1. Margie Campbell
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Susanne Corisdeo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Clair McGee
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Denny Kraichely
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Margie Campbell.

Additional information

Molecular Biotechnology—9th Peace Conference Proceedings

Rights and permissions

Reprints and permissions

About this article

Cite this article

Campbell, M., Corisdeo, S., McGee, C. et al. Utilization of Site-Specific Recombination for Generating Therapeutic Protein Producing Cell Lines. Mol Biotechnol 45, 199–202 (2010). https://doi.org/10.1007/s12033-010-9266-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12033-010-9266-5

Keywords

Search

Navigation